DE EN Anmelden

In your studies 'Drug Regulator Affairs'

©Volker Lannert / Universität Bonn

Master's thesis


As part of the continuing education Master's degree programme, Master's theses are written on relevant topics in the field of 'Drug Regulatory Affairs' using scientific methods. The topics are highly topical, diverse and the results are both of interest in a scientific context and relevant to many areas of activity in 'Drug Regulatory Affairs'.

Here you will find all Master's theses written since the year 2000, including the title and a summary. In this collection, many Master's theses can also be viewed and downloaded in full text.

Further information on Master's theses (e.g. registration, processing) can be found in our ‘Master's thesis guidelines/Leitfaden für die Anfertigung einer Masterarbeit’ (in German) and in the ‘Information leaflet - Master's thesis’ at

Downloads from A-Z

Do you have any questions or are you interested in the full text of a Master's thesis that is not listed here?
Please feel free to contact me.

Dr. Jasmin Fahnenstich

Dr. Jasmin Fahnenstich

Study programme manager

Phone: +49 (0) 228 - 9268 6806

Send e-mail

Master's thesis

The collection of Master's theses can be searched and sorted by entering keywords.

Year Name Title Full text Summary
2012 Ulrich Härtel Clinical trial standard protocols, approaches for more regulatory efficiency? ***
2012 Dr. Martin M. Hartge HTA of orphan oncological medicinal products - A current critical assessment and discussion from authority, KOL and industry point of view
2012 Pia Helfrich Investigator-Initiated Trials on Medical Devices - Legal Basis and Regulatory Aspects ***
2012 Dr. Leonie Hempel Challenges and Chances of the Development of Biosimilar Monoclonal Antibodies in the EU
2012 Dr. Matthias Hübner Worldwide Regulatory Strategy for the Development and Submission of a Recombinant Product antagonizing the Action of a Medicinal Product ***
2012 Dr. Viktor Ivandic Methodological Requirements for Early Benefit Assessment in Germany (G-BA/ IQWIG) and Single Technology Appraisal in England (NICE) - a Comparison ***
2012 Angelika Kamp 2 years Variation Regulation: A retrospective critical assessment from the industrial perspective ***
2012 Karen Koch An Overview of the Orphan Drug Status which has been put in place in countries in order to stimulate the research and development of treatments of rare diseases
2012 Martina Krüger Haberkamp Das Qualitätsmanagement im Blutspendewesen am Beispiel des Blutspendedienstes der Bundeswehr
2012 Judith Leyendecker Identification of Commercially Confidential Information and Protection of Personal Data - New transparency guidance (1st publication: June 2011) of EMA and HMA especially from the point of view of service companies
2012 Dr. Florence Loeffler Veterinary medicinal products for horses in the European Union - an overview
2012 Dr. Jana Nissen Prostaglandin analogues as lash enhancers - cosmetics or medicinal products?
2012 Olof Palme Current Developments in Electronic Regulatory Affairs and Their Impact on Small and Medium-Sized Enterprises
2012 Dr. Karin Schlegel Risk Management Plan - The Legislative Changes with Directive 2010/84/EC and Regulation (EC) No 1235/2010
2012 Dr. Janinne Sylvie Schmid Regulatory challenges for the registration of generic transdermal patches - A Guidance for Regulatory Affairs
2012 Dr. Laurent Schmitt An overview of the incentives in the EU and USA and their draw backs to promote drugs for the treatment of rare diseases ***
2012 Dr. Andrea Schüssele Radiopharmaceuticals - are their peculiarities adequately reflected in European legislation? ***
2012 Sonja Seeberger The new Falsified Medicine Directive 2011/62/EU and its requirements for stakeholders ***
2012 Dr. Anaid Shahbazian Sicherheit bei Medizinprodukten in Deutschland am Beispiel steriler wiederverwendbarer Instrumente in der Ophthalmologie
2012 Dr. Gabriele Sigl-Seifert Regulatorische Analyse der frühen Nutzenbewertung von Linagliptin, einem innovativen oralen Antidiabetikum
  • Total: 969